Hookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Decrease in Short Interest

Hookipa Pharma Inc (NASDAQ:HOOK) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 66,200 shares, a decrease of 21.3% from the February 13th total of 84,100 shares. Based on an average daily volume of 122,100 shares, the short-interest ratio is presently 0.5 days. Approximately 1.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Royal Bank of Canada downgraded Hookipa Pharma from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $48.00 to $2.00 in a report on Friday, December 20th. JMP Securities dropped their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Hookipa Pharma in a report on Friday, January 10th.

Hookipa Pharma Price Performance

Shares of Hookipa Pharma stock traded down $0.05 on Wednesday, reaching $1.20. 19,089 shares of the company were exchanged, compared to its average volume of 74,281. The stock’s 50 day moving average price is $1.72 and its 200-day moving average price is $2.80. The company has a market cap of $14.46 million, a P/E ratio of -0.32 and a beta of 0.71. Hookipa Pharma has a 1-year low of $1.11 and a 1-year high of $10.50.

Institutional Investors Weigh In On Hookipa Pharma

Several institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in Hookipa Pharma in the fourth quarter valued at $31,000. Squarepoint Ops LLC acquired a new position in Hookipa Pharma in the fourth quarter valued at approximately $104,000. Ikarian Capital LLC purchased a new position in Hookipa Pharma in the third quarter valued at approximately $228,000. Finally, Gilead Sciences Inc. acquired a new stake in Hookipa Pharma during the fourth quarter worth approximately $3,771,000. 63.88% of the stock is owned by hedge funds and other institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.